Results 221 to 230 of about 5,124 (246)

Dabigatran-idarucizumab pharmacokinetics-pharmacodynamics in sheep undergoing cardiopulmonary bypass.

Perfusion
BackgroundThe effect of the anticoagulant, dabigatran, and its antagonist, idarucizumab, on coagulation remains poorly quantified. There are few pharmacokinetic-pharmacodynamic data available to describe the interaction in humans or animals undergoing ...
Michael P Eaton, S. Nadtochiy, Tatsiana Stefanos, B. Anderson   +3 more
semanticscholar   +1 more source

Eluxadoline, Lesinurad, and Idarucizumab

Journal of the American Pharmacists Association, 2016
Irritable bowel syndrome (IBS) is estimated to affect 10% to 15% of adults in the United States. Some patients with IBS experience diarrhea as the most common manifestation (IBS-D), and others experience constipation as the most commonmanifestation (IBS-C).
Daniel A, Hussar, Maggie, Gandhi
openaire   +2 more sources

Idarucizumab for dabigatran overdose

Clinical Toxicology, 2016
An overdose of oral anticoagulants represents a challenging scenario for emergency physicians. Dabigatran, an oral direct thrombin inhibitor, is increasingly used in place of warfarin. The lack of an antidote is a concern in patients who overdose on dabigatran, even though the drug can be eliminated with hemodialysis.
Marijke, Peetermans, Charles, Pollack, Paul, Reilly, Laurens, Liesenborghs, Marc, Jacquemin, Jerrold H, Levy, Jeffrey I, Weitz, Peter, Verhamme   +7 more
openaire   +2 more sources

Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany—Updated series of 120 cases

International Journal of Stroke, 2020
Background Idarucizumab is a monoclonal antibody fragment with high affinity for dabigatran reversing its anticoagulant effects within minutes. Thereby, patients with acute ischemic stroke who are on dabigatran treatment may become eligible for ...
P. Kermer, C. Eschenfelder, H. Diener, M. Grond, Y. Abdalla, Alexej Abraham, K. Althaus, Gebhard Becks, J. Berrouschot, Jörg Berthel, F. Bode, L. Burghaus, H. Cangür, M. Daffertshofer, Sebastian Edelbusch, J. Eggers, R. Gerlach, K. Gröschel, F. Grosse-Dresselhaus, A. Günther, C. Haase, C. Haensch, A. Harloff, J. Heckmann, V. Held, M. Hieber, A. Kauert, R. Kern, T. Kerz, M. Köhrmann, P. Kraft, P. Kühnlein, J. Latta, E. Leinisch, Arne Lenz, C. Leithner, T. Neumann-Haefelin, M. Mäurer, W. Müllges, C. Nolte, M. Obermann, S. Partowi, Peer Patzschke, S. Poli, U. Pulkowski, J. Purrucker, T. Rehfeldt, P. Ringleb, J. Röther, ra Rossi, Hazem El-Sabassy, O. Sauer, G. Schackert, N. Schäfer, P. Schellinger, Andreas Schneider, R. Schuppner, S. Schwab, Olav Schwarte, R. Seitz, S. Senger, Y. Shah, E. Sindern, P. Sparenberg, T. Steiner, K. Szabo, Christian Urbanek, Bettina von Sarnowksi, K. Weissenborn, P. Wienecke, K. Witt, Robert Wruck, S. Wunderlich   +72 more
semanticscholar   +1 more source

Reversal of Dabigatran with Idarucizumab

Expert Review of Cardiovascular Therapy, 2016
The use of novel oral anticoagulants such as dabigatran has been increasing over the last five years. Indicated for use in the prevention of thromboembolic complications from non-valvular atrial fibrillation and for the treatment and prevention of venous thromboembolic disease, dabigatran is increasingly encountered clinically.
Neel R, Sodha, Frank W, Sellke
openaire   +2 more sources

Stroke reperfusion therapy following dabigatran reversal with idarucizumab in a national cohort

Neurology, 2020
Objective To assess the frequency and utilization trends of dabigatran reversal with idarucizumab and compare associated complications, outcomes, and door-to-needle times to those of patients not exposed to idarucizumab in a nationwide cohort of ...
P. A. Barber, Teddy Y. Wu, A. Ranta
semanticscholar   +1 more source

Idarucizumab: First Global Approval

Drugs, 2015
Idarucizumab (Praxbind(®)) is a fully humanized, monoclonal antibody fragment developed by Boehringer Ingelheim as a specific antidote to reverse the anticoagulant effect of the direct oral thrombin inhibitor dabigatran etexilate (Pradaxa(®)). Idarucizumab received its first global approval, in the USA, in October 2015 for use in adult patients treated
openaire   +2 more sources

Idarucizumab: What Should We Know?

Current Drug Targets, 2018
Idarucizumab, a humanized monoclonal antibody fragment acting as a specific antidote for dabigatran, is approved for reversing the dabigatran-associated possible bleeding from critical sites or bleeding persisting despite local post-procedure haemostasis.
Cortese F., Calculli G., Gesualdo M., Cecere A., Zito A., De Vito F., Carbonara R., Carbonara S., Cortese A. M., Ciccone M. M.   +9 more
openaire   +4 more sources

Incomplete dabigatran reversal with idarucizumab

Clinical Toxicology, 2017
With increasing use of direct oral anticoagulants (DOACs), urgent reversal of these agents becomes a growing concern. Idarucizumab is a humanized monoclonal antibody fragment that specifically binds to dabigatran with higher affinity than thrombin, rapidly neutralizing its anticoagulant effect without increased risk of thrombosis.We describe two cases ...
Aaron P. Steele, Jin A. Lee, William E. Dager   +2 more
openaire   +2 more sources

Standard operating procedure for idarucizumab reversal of dabigatran anticoagulation in ischemic and hemorrhagic stroke

Journal of Thrombosis and Thrombolysis, 2023
Senta Frol, J. P. Oblak, M. Šabovič, P. Kermer   +3 more
semanticscholar   +1 more source